Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Z651210-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$500.90
|
|
|
Z651210-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$850.90
|
|
|
Z651210-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,750.90
|
|
| Synonyms | AKOS040742836 | HY-15072 | YM872 | YM-872 | Zonampanel [USAN:INN] | Q21098871 | 2-(7-imidazol-1-yl-6-nitro-2,3-dioxo-4H-quinoxalin-1-yl)acetic acid | Zonampanel anhydrous | SCHEMBL678832 | Ym 872 | 7-(1H-Imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxa |
|---|---|
| Specifications & Purity | ≥98% |
| Biochemical and Physiological Mechanisms | Zonampanel (YM 872) is a selective antagonist of the glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor . |
| Storage Temp | Store at 2-8°C,Protected from light,Desiccated |
| Shipped In |
Wet ice This product requires cold chain shipping. Ground and other economy services are not available. |
| Action Type | ANTAGONIST |
| Mechanism of action | Glutamate receptor ionotropic AMPA antagonist |
| Product Description |
Zonampanel (YM 872) is a selective antagonist of the glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor . In Vitro Zonampanel inhibits the human MRP4-mediated transport of [ 3 H]oestradiol 17-D-glucuronide in a concentration-dependent manner. In contrast, Zonampanel (up to 1000 mM) does not inhibit the human MRP2- or BCRP-mediated transport of [ 3 H]oestradiol 17-D-glucuronide or [ 3 H]methotrexate. Zonampanel inhibits the uptake of typical substrates by Oat1, Oat2, and Oat3 with inhibition constant (K i ) values of 7.02 to 10.4 μM. A time- and saturable concentration-dependent increase in [ 14 C]Zonampanel uptake is observed in these cells [K m values: 13.4 to 53.6 μM]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo In in vivo experiments, probenecid and cimetidine decrease intrinsic clearance for both the renal secretion and biliary excretion of Zonampanel. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal administration Seven-week-old male Sprague-Dawley rats are used at 8 weeks after acclimatization for at least 1 week. During acclimatization, the rats are kept in an air-conditioned room with temperature and humidity controlled at 22.9 to 23.3°C and 50 to 78%; the room is lit for 12 h 30 min from 7:30 AM to 8:00 PM. Rats are given free access to solid food and water until just before drug administration. YM 872 (15 mg/kg) is administered at a single bolus dose into the rat tail vein with or without probenecid (50 mg/kg) or cimetidine (40 mg/kg). At 5, 15, and 30 min and 1, 2, 3, 4, and 6 h after dosing, blood is sampled under ether anesthesia via the inferior vena cava using a heparinized syringe and immediately stored on ice using four rats each per sampling time point per administration group (total of 128 rats for 8 sampling time points and 4 administration groups). Plasma is obtained by centrifugation at 4°C, 1870 g for 15 min and kept frozen at -20°C. Rats for plasma sampling at 3 and 6 h after administration are housed in metabolic cages after administration, spontaneously excreted urine is collected, and the cages are washed using water. Regarding specific gravity as 1, urine volume (including the cage-wash water) is calculated according to differences in the weight of the sampling tube before and after sampling. Urine samples are kept frozen at -20°C until assay as described below. All plasma and urine samples are protected from light throughout the sampling, storage, and assay procedures. aladdin has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Class | Diazanaphthalenes |
| Subclass | Benzodiazines |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Quinoxalines |
| Alternative Parents | Alpha amino acids and derivatives Imidazolyl carboxylic acids and derivatives Nitroaromatic compounds Pyrazines Benzenoids N-substituted imidazoles Heteroaromatic compounds Lactams Propargyl-type 1,3-dipolar organic compounds Azacyclic compounds Carboxylic acids Organic oxoazanium compounds Monocarboxylic acids and derivatives Organonitrogen compounds Hydrocarbon derivatives Organic zwitterions Carbonyl compounds Organopnictogen compounds Organic oxides |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Alpha-amino acid or derivatives - Quinoxaline - Nitroaromatic compound - Imidazolyl carboxylic acid derivative - N-substituted imidazole - Pyrazine - Benzenoid - Heteroaromatic compound - Imidazole - Azole - Organic nitro compound - Lactam - C-nitro compound - Propargyl-type 1,3-dipolar organic compound - Allyl-type 1,3-dipolar organic compound - Azacycle - Organic 1,3-dipolar compound - Carboxylic acid derivative - Carboxylic acid - Organic oxoazanium - Monocarboxylic acid or derivatives - Organic oxide - Organic nitrogen compound - Organonitrogen compound - Organic oxygen compound - Hydrocarbon derivative - Organooxygen compound - Carbonyl group - Organopnictogen compound - Organic zwitterion - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as quinoxalines. These are compounds containing a quinoxaline moiety, a bicyclic heterocycle made up of a benzene ring fused to a pyrazine ring. |
| External Descriptors | Not available |
|
|
|
| ALogP | -0.2 |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IUPAC Name | 2-(7-imidazol-1-yl-6-nitro-2,3-dioxo-4H-quinoxalin-1-yl)acetic acid |
|---|---|
| INCHI | InChI=1S/C13H9N5O6/c19-11(20)5-17-8-4-9(16-2-1-14-6-16)10(18(23)24)3-7(8)15-12(21)13(17)22/h1-4,6H,5H2,(H,15,21)(H,19,20) |
| InChIKey | SPXYHZRWPRQLNS-UHFFFAOYSA-N |
| Smiles | C1=CN(C=N1)C2=C(C=C3C(=C2)N(C(=O)C(=O)N3)CC(=O)O)[N+](=O)[O-] |
| Isomeric SMILES | C1=CN(C=N1)C2=C(C=C3C(=C2)N(C(=O)C(=O)N3)CC(=O)O)[N+](=O)[O-] |
| Alternate CAS | 210245-80-0 |
| PubChem CID | 148200 |
| MeSH Entry Terms | (2,3-dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3,4-tetrahydro-1-quinoxalinyl)acetic acid monohydrate;YM 872;YM-872;YM872;zonampanel monohydrate |
| Molecular Weight | 331.24 |
| Solubility | DMSO : 50 mg/mL (150.95 mM; ultrasonic and warming and heat to 60°C) |
|---|---|
| Molecular Weight | 331.240 g/mol |
| XLogP3 | -0.200 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 3 |
| Exact Mass | 331.055 Da |
| Monoisotopic Mass | 331.055 Da |
| Topological Polar Surface Area | 150.000 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 578.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |